Accueil > Actualité
Actualite financiere : Actualite bourse

Novartis: arthritis drug meets goal in late-stage trial

( - Novartis said that its psoriasis drug Cosentyx has met the primary endpoint of a final stage trial for the treatment of patients with axial spondyloarthritis, showing a "significant and clinically meaningful" reduction in disease activity.

The ongoing Phase III trial, - which enrolled 555 male and female adult patients with active non-radiographic axial spondyloarthritis - met its primary endpoint at week 16, taking the treatment one step toward its final marketing approval.

There are approximately 1.7 million patients with non-radiographic axial spondyloarthritis in the EU and US.

The disease entails chronic inflammatory back pain and other symptoms such as nocturnal pain.

Copyright (c) 2019 All rights reserved.




Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.
Indices et cours différés d’au moins 15 mn | Cotations boursières fournies par ABC Bourse.